HYLENEX RECOMBINANT Drug Profile
✉ Email this page to a colleague
Summary for Tradename: HYLENEX RECOMBINANT
High Confidence Patents: | 4 |
Applicants: | 1 |
BLAs: | 1 |
Recent Clinical Trials: | See clinical trials for HYLENEX RECOMBINANT |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for HYLENEX RECOMBINANT |
Recent Clinical Trials for HYLENEX RECOMBINANT
Identify potential brand extensions & biosimilar entrants
Sponsor | Phase |
---|---|
The Wistar Institute | Phase 1 |
Pablo Tebas | Phase 1 |
Inovio Pharmaceuticals | Phase 1 |
Recent Litigation for HYLENEX RECOMBINANT
Identify key patents and potential future biosimilar entrants
District Court Litigation
Case Name | Date |
---|---|
Halozyme, Inc. v. Lee | 2016-12-19 |
Halozyme, Inc. v. Lee | 2016-12-18 |
Pharmacology for HYLENEX RECOMBINANT
Established Pharmacologic Class | Endoglycosidase |
Chemical Structure | Glycoside Hydrolases |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- General brand-side disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for HYLENEX RECOMBINANT Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for HYLENEX RECOMBINANT Derived from Company Disclosures
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
---|---|---|---|---|---|---|---|
Halozyme Therapeutics, Inc. | HYLENEX RECOMBINANT | hyaluronidase human | Injection | 021859 | 7,767,429 | 2039-09-22 | Company disclosures |
Halozyme Therapeutics, Inc. | HYLENEX RECOMBINANT | hyaluronidase human | Injection | 021859 | 8,202,517 | 2023-03-05 | Company disclosures |
Halozyme Therapeutics, Inc. | HYLENEX RECOMBINANT | hyaluronidase human | Injection | 021859 | 8,431,124 | 2023-03-05 | Company disclosures |
Halozyme Therapeutics, Inc. | HYLENEX RECOMBINANT | hyaluronidase human | Injection | 021859 | 8,431,380 | 2023-03-05 | Company disclosures |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
3) Low Certainty: US Patents for HYLENEX RECOMBINANT Derived from Patent Text Search
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
---|---|---|---|---|---|---|---|
Halozyme Therapeutics, Inc. | HYLENEX RECOMBINANT | hyaluronidase human | Injection | 021859 | 11,414,489 | Patent claims search | |
Halozyme Therapeutics, Inc. | HYLENEX RECOMBINANT | hyaluronidase human | Injection | 021859 | 6,258,791 | 2017-05-29 | Patent claims search |
Halozyme Therapeutics, Inc. | HYLENEX RECOMBINANT | hyaluronidase human | Injection | 021859 | 8,273,721 | 2028-03-05 | Patent claims search |
Halozyme Therapeutics, Inc. | HYLENEX RECOMBINANT | hyaluronidase human | Injection | 021859 | 8,460,381 | 2039-02-26 | Patent claims search |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
International Patents for HYLENEX RECOMBINANT
Country | Patent Number | Estimated Expiration |
---|---|---|
Cyprus | 2016024 | ⤷ Try for Free |
Portugal | 1603541 | ⤷ Try for Free |
Portugal | 2177620 | ⤷ Try for Free |
Poland | 2177620 | ⤷ Try for Free |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for HYLENEX RECOMBINANT
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|
122015000061 | Germany | ⤷ Try for Free | PRODUCT NAME: TRASTUZUMAB UND RECOMBINANTE HUMANE HYALURONIDASE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826 |
CR 2016 00031 | Denmark | ⤷ Try for Free | PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; NAT. REG. NO/DATE: EU/1/98/067/003-004 20140326; FIRST REG. NO/DATE: EU EU/1/98/067 20140326 |
132016000025345 | Italy | ⤷ Try for Free | PRODUCT NAME: TRASTUZUMAB PER USO SOTTOCUTANEO(HERCEPTIN); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/00/145/002, 20130828 |
300822 | Netherlands | ⤷ Try for Free | PRODUCT NAME: RITUXIMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/98/067/003 20140326 |
>Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Market Dynamics and Financial Trajectory for Hylenex Recombinant
More… ↓